Article

Azacitidine Response in Myelodysplastic Syndromes is Marked by NK-like CD8 T-Cell Expansion and CXCL12+ Reticular Cell Remodeling

2026-07-08

Abstract excerpt

Myelodysplastic syndromes (MDS) are driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs), leading to clonal expansion and ineffective hematopoiesis. Hypomethylating agents (HMAs; azacitidine or decitabine) are the standard of care for higher-risk MDS. However, their effects on the bone marrow (BM) microenvironment, and the extent to which these changes correlate with clinical response, re...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3285a1cc-425d-5d97-bebf-ea5b373dd0c9
DOI: 10.64898/2026.07.07.736922

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Azacitidine Response in Myelodysplastic Syndromes is Marked by NK-like CD8 T-Cell Expansion and CXCL12+ Reticular Cell RemodelingDOI 10.64898/2026.07.07.736922Read

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read

Unique epigenomic signatures identify biologically significant subtypes of MDS and predict response to azacitidineSemantic proximity Read

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read

Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasmsSemantic proximity Read

Clinical Response to Azacitidine in Myelodysplastic Neoplasms is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor cells<i>in vivo</i>Semantic proximity Read

Single cell multiomics reveal clonal and functional dynamics of MDS stem/progenitor cells during hypomethylating therapySemantic proximity Read

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related diseaseSemantic proximity Read

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic SyndromesSemantic proximity Read

Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCsSemantic proximity Read

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studySemantic proximity Read

The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformationsSemantic proximity Read

Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.Semantic proximity Read